Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients

European Heart Journal

Volumn 29, Issue 8, 2008, Pages 1011-1018

  Pascual Figal, Domingo A ^a   Domingo, Maite ^b   Casas, Teresa ^a   Gich, Ignasi ^c   Ordoñez Llanos, Jordi ^b   Martínez, Pedro ^a   Cinca, Juan ^b   Valdés, Mariano ^a   Januzzi, James L ^d   Bayes Genis, Antoni ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

B type natriuretic peptide; Clinical score; Heart failure; Outpatient; Prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT;

BIOLOGICAL MARKERS; EPIDEMIOLOGIC METHODS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OUTPATIENTS; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 45349090915     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn023     Document Type: Article

References (23)

1. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-735.
2. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-167.
3. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735- 1743.
4. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, vonScheidt W. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J Am Coll Cardiol 2001;38:1934-1941.
5. Tang WH, Girod JP, Lee MJ, Starling RC, Young JB, Van LF, Francis GS. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation 2003;108:2964-2966.
6. Munagala VK, Burnett JC Jr, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004;29:707-769.
7. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004;110:2168- 2174.
8. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004;43:635-641.
9. Bayes-Genis A, Pascual-Figal D, Fabregat J, Domingo M, Planas F, Casas T, Ordonez-Llanos J, Valdes M, Cinca J. Serial NT-proBNP monitoring and outcomes in outpatients with decompensation of heart failure. Int J Cardiol 2007;120:338-343.
10. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
11. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22(Suppl. A):6A-13A.
12. Knebel F, Schimke I, Pliet K, Schattke S, Martin S, Borges AC, Baumann G. NT-ProBNP in acute heart failure: correlation with invasively measured hemodynamic parameters during recompensation. J Card Fail 2005;11(Suppl. 5):S38-S41.
13. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001;7:21-29.
14. Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, Hulot JS, Thomas D, Piwowarska W, Komajda M. Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004;25:1788-1796.
15. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-391.
16. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-1283.
17. Bettencourt P, Frioes F, Azevedo A, Dias P, Pimenta J, Rocha-Goncalves F, Ferreira A. Prognostic information provided by serial measurements of brain natriuretic peptide in heart failure. Int J Cardiol 2004;93:45-48.
18. Yan RT, White M, Yan AT, Yusuf S, Rouleau JL, Maggioni AP, Hall C, Latini R, Afzal R, Floras J, Masson S, McKelvie RS. Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. Am J Cardiol 2005;96:698-704.
19. Fujimura M, Yasumura Y, Ishida Y, Nakatani S, Komamura K, Yamagishi M, Miyatake K. Improvement in left ventricular function in response to carvedilol is accompanied by attenuation of neurohumoral activation in patients with dilated cardiomyopathy. J Card Fail 2000;6:3-10.
20. Richards M, Troughton RW. NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 2004;6:351-354.
21. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, Juilliere Y. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure (The STARS-BNP multicenter study). J Am Coll Cardiol 2007;49:1733-1739.
22. Wu AH, Smith A, Apple FS. Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure. Am J Cardiol 2004;93:1562-1563.
23. Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004;6:355-358.